menu
    • menu
    [{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Lotus Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ Lotus Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ Lotus Pharmaceutical"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ Coherus Biosciences","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ Coherus Biosciences"},{"orgOrder":0,"company":"Klinge Pharma","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Aflibercept","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Klinge Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Klinge Pharma \/ MS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Klinge Pharma \/ MS Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Klinge Pharma

    Menu

    Klinge Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Lotus Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lotus Becomes Strategic Partner for the Commercialization of Biosimilar Ahzantive

                            Details : Through the collaboration, Lotus will lead the commercialization of Ahzantive (Aflibercept) in the designated regions, a biosimilar candidate to Eylea.

                            Product Name : Ahzantive

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 05, 2025

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Lotus Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Teva Partners to Commercialize Formycon Biosimilar Candidate in Europe, Israel

                            Details : Through the collaboration, Teva will lead the commercialization of Ahzantive (Aflibercept) in the designated regions, a biosimilar candidate to Eylea.

                            Product Name : Ahzantive

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : MS Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MS Pharma Partners for FYB203 Biosimilar Commercialization in MENA Region

                            Details : MS Pharma becomes a partner for the commercialization of FYB203, Formycon’s Biosimilar to Eylea® (Aflibercept), in the MENA Region for the treatment of neovascular age-related macular degeneration.

                            Product Name : FYB203

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 14, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : MS Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed

                            Klinge Pharma

                            Germany arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Coherus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

                            Details : FYB203, a biosimilar candidate to Eylea (aflibercept), which Klinge Biopharma has in-licensed from the German biosimilar developer Formycon AG, is being evaluated in a Phase 3 clinical trial in patients with Neovascular (wet) Age-Related Macular Degenera...

                            Product Name : FYB203

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $32.5 million

                            September 01, 2023

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Coherus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth